Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned a consensus rating of “Moderate Buy” from the sixteen brokerages that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $55.36.

NTLA has been the topic of several research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a report on Thursday, September 19th. Wedbush reissued a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a report on Thursday, November 7th. Citigroup lowered their price target on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Robert W. Baird reduced their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. The trade was a 4.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of NTLA. Dimensional Fund Advisors LP boosted its position in shares of Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after acquiring an additional 98,865 shares during the last quarter. Thrivent Financial for Lutherans purchased a new stake in shares of Intellia Therapeutics during the 2nd quarter valued at approximately $679,000. American Century Companies Inc. lifted its holdings in Intellia Therapeutics by 23.8% in the second quarter. American Century Companies Inc. now owns 330,514 shares of the company’s stock valued at $7,397,000 after acquiring an additional 63,550 shares during the last quarter. Comerica Bank grew its position in Intellia Therapeutics by 853.6% in the first quarter. Comerica Bank now owns 37,105 shares of the company’s stock worth $1,021,000 after acquiring an additional 33,214 shares during the period. Finally, Vanguard Group Inc. increased its stake in Intellia Therapeutics by 8.9% during the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after acquiring an additional 746,263 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Trading Down 7.6 %

NASDAQ NTLA opened at $13.97 on Friday. Intellia Therapeutics has a 12-month low of $13.95 and a 12-month high of $34.87. The company has a fifty day simple moving average of $18.75 and a two-hundred day simple moving average of $22.09. The stock has a market cap of $1.42 billion, a P/E ratio of -2.57 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. The business’s revenue was down 24.1% on a year-over-year basis. During the same quarter last year, the business earned ($1.38) EPS. As a group, sell-side analysts forecast that Intellia Therapeutics will post -5.13 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.